Template:Chemical SUIT-032 NADH mt D078: Difference between revisions
From Bioblast
No edit summary |
No edit summary |
||
| (7 intermediate revisions by the same user not shown) | |||
| Line 17: | Line 17: | ||
| 4Myx | | 4Myx | ||
| {{Template:Myxothiazol}} | | {{Template:Myxothiazol}} | ||
| | | We do not recommend the use of any other inhibitor of complex III, like {{Template:Antimycin A}}, due to the chemical background effect on fluorescence. | ||
|- | |- | ||
| | | 5Reox | ||
| | | | ||
| Reoxygenation can be performed by opening the chamber, see: [[Open chamber]]. | |||
|} | |} | ||
Latest revision as of 11:40, 2 January 2024
| Step | Chemical(s) and link(s) | Comments |
|---|---|---|
| 1PGM | Pyruvate (P), Glutamate (G), and Malate (M) | |
| 2D | ADP (D) | |
| 3Anox | The O2 concentration in the O2k-chamber can be decreased by N2 or H2 injection to reach faster anoxia, see: Setting the oxygen concentration. | |
| 4Myx | Myxothiazol | We do not recommend the use of any other inhibitor of complex III, like Antimycin A (Ama), due to the chemical background effect on fluorescence. |
| 5Reox | Reoxygenation can be performed by opening the chamber, see: Open chamber. |
